Published in Cancer Epidemiol Biomarkers Prev on November 01, 1997
Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer (2008) 4.34
Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst (2010) 2.80
Supplement use and risk of cutaneous squamous cell carcinoma. J Am Acad Dermatol (2011) 1.52
A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer. Cancer Prev Res (Phila) (2010) 1.21
Basal cell carcinoma: from the molecular understanding of the pathogenesis to targeted therapy of progressive disease. J Skin Cancer (2010) 1.06
A phase III skin cancer chemoprevention study of DFMO: long-term follow-up of skin cancer events and toxicity. Cancer Prev Res (Phila) (2012) 0.84
Updated Physician's Guide to the Off-label Uses of Oral Isotretinoin. J Clin Aesthet Dermatol (2014) 0.77
Retinoids for prevention and treatment of actinic keratosis. An Bras Dermatol (2013) 0.75
Dose response of retinol and isotretinoin in the prevention of nonmelanoma skin cancer recurrence. Nutr Cancer (2010) 0.75
Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science (1997) 7.95
A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med (1995) 6.14
Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol (2000) 6.06
Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med (1978) 5.78
Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia (1989) 2.90
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene (2012) 2.41
Diffusion tensor imaging of the brain: review of clinical applications. Neuroradiology (2004) 2.37
Direct cloning of human ovarian carcinoma cells in agar. Cancer Res (1978) 2.24
Colon cancer reduction. Questions about implementation of proven techniques. Arch Intern Med (1997) 2.12
Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial. J Natl Cancer Inst (1994) 2.05
Surfactant protein D stimulates phagocytosis of Pseudomonas aeruginosa by alveolar macrophages. Am J Respir Cell Mol Biol (1999) 2.04
Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res (1997) 1.96
Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res (1995) 1.94
Adenoma characteristics as risk factors for recurrence of advanced adenomas. Gastroenterology (2001) 1.88
Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E. Cancer Epidemiol Biomarkers Prev (2001) 1.87
Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer (1976) 1.85
Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res (1986) 1.75
Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol Cell Biol (1997) 1.68
Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med (1979) 1.57
Slowly fading super-luminous supernovae that are not pair-instability explosions. Nature (2013) 1.52
Dose response evaluation of adriamycin in human neoplasia. Cancer (1977) 1.51
Characterization of the activating region of Escherichia coli catabolite gene activator protein (CAP). I. Saturation and alanine-scanning mutagenesis. J Mol Biol (1994) 1.50
Inhibitory effect of six green tea catechins and caffeine on the growth of four selected human tumor cell lines. Anticancer Drugs (1996) 1.49
Characterization of a calcium-activated chloride channel as a shared target of Th2 cytokine pathways and its potential involvement in asthma. Am J Respir Cell Mol Biol (2001) 1.47
Analogues of amonafide and azonafide with novel ring systems. J Med Chem (2000) 1.47
Effect of beta-carotene on lymphocyte subpopulations in elderly humans: evidence for a dose-response relationship. Am J Clin Nutr (1991) 1.45
Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep (1976) 1.45
beta-Carotene treatment of cervical intraepithelial neoplasia: a phase II study. Cancer Epidemiol Biomarkers Prev (1996) 1.43
Reliability and validity of a self-administered food frequency questionnaire in a chemoprevention trial of adenoma recurrence. Cancer Epidemiol Biomarkers Prev (1999) 1.42
Design of antineoplastic agents on the basis of the "2-phenylnaphthalene-type" structural pattern. 2. Synthesis and biological activity studies of benzo]b]naphtho[2,3-d]furan-6,11-dione derivatives. J Med Chem (1993) 1.41
Alcohol intake and early-onset basal cell carcinoma in a case-control study. Br J Dermatol (2014) 1.38
GM-CSF, carboplatin, doxorubicin: a phase I study. Cancer Chemother Pharmacol (1994) 1.38
Comparison of bone scintigraphy and radiography in multiple myeloma. Radiology (1980) 1.37
Neutrophil-mediated epithelial injury during transmigration: role of elastase. Am J Physiol Gastrointest Liver Physiol (2001) 1.33
In-vitro clonogenic assay for predicting response of ovarian cancer to chemotherapy. Lancet (1980) 1.30
Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol (1998) 1.29
Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer (1998) 1.27
The czc operon of Alcaligenes eutrophus CH34: from resistance mechanism to the removal of heavy metals. J Ind Microbiol (1995) 1.27
The role of radiotherapy in the treatment of malignant sweat gland neoplasms. Cancer (1990) 1.26
Herpes gestationis: clinical and histologic features of twenty-eight cases. J Am Acad Dermatol (1983) 1.26
A nonsense mutation causes hereditary goitre in the Afrikander cattle and unmasks alternative splicing of thyroglobulin transcripts. Proc Natl Acad Sci U S A (1987) 1.26
Measurement of chemopreventive efficacy in skin biopsies. Anal Quant Cytol Histol (2001) 1.25
Loss of annexin II heavy and light chains in prostate cancer and its precursors. Cancer Res (2001) 1.25
Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft. Cancer Res (1997) 1.24
Regulation of neutrophil activation in acute lung injury. Chest (1999) 1.23
Dose de-escalation chemoprevention trial of alpha-difluoromethylornithine in patients with colon polyps. J Natl Cancer Inst (1994) 1.23
High-dose dexamethasone for prevention of cis-platin-induced vomiting. Cancer Chemother Pharmacol (1981) 1.21
Attitudes and practices of primary care physicians for prostate cancer screening. Am J Prev Med (1997) 1.21
Karyometry in the early detection and chemoprevention of intraepithelial lesions. Eur J Cancer (2005) 1.20
Pharmacokinetics of very high-dose oral melphalan in cancer patients. Am J Clin Oncol (1990) 1.20
Cutaneous plasmacytomas in myeloma. Relationship to tumor cell burden. Arch Dermatol (1978) 1.19
Malignant melanoma in southern Arizona. Increasing incidence and sunlight as an etiologic factor. Arch Dermatol (1981) 1.19
Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona, 1985-1996. J Am Acad Dermatol (2001) 1.18
Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma. Blood (1980) 1.18
The pharmacokinetics of daunomycin in man. Clin Pharmacol Ther (1971) 1.16
Surfactant protein A enhances alveolar macrophage phagocytosis of a live, mucoid strain of P. aeruginosa. Am J Physiol (1999) 1.16
Amplification of 19q13.1-q13.2 sequences in ovarian cancer. G-band, FISH, and molecular studies. Cancer Genet Cytogenet (1996) 1.15
Dexamethasone as an antiemetic in patients treated with cisplatin. N Engl J Med (1981) 1.14
Incidence of meningeal involvement by rhabdomyosarcoma of the head and neck in children: a report of the Intergroup Rhabdomyosarcoma Study (IRS). Cancer (1978) 1.14
Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin Cancer Res (2000) 1.13
The effect of phenobarbital on cyclophosphamide antitumor activity. Cancer Res (1976) 1.13
Nuclear morphometry in solar keratosis. Anal Quant Cytol Histol (1998) 1.12
Risk factors for Ki-ras protooncogene mutation in sporadic colorectal adenomas. Cancer Res (1999) 1.12
Influence of time and therapy on ventricular defibrillation in dogs. Crit Care Med (1980) 1.12
Extent of white matter lesions is related to acute subcortical infarcts and predicts further stroke risk in patients with first ever ischaemic stroke. J Neurol Neurosurg Psychiatry (2005) 1.11
Cloning of TC-1 (C8orf4), a novel gene found to be overexpressed in thyroid cancer. Genomics (2000) 1.10
Hydrolysis and protein binding of melphalan. J Pharm Sci (1978) 1.10
Analysis of the p53 gene in human precancerous actinic keratosis lesions and squamous cell cancers. Cancer Lett (1994) 1.10
Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine. Cancer Epidemiol Biomarkers Prev (2000) 1.09
Corrected nucleotide sequence of M13mp18 gene III. Gene (1992) 1.08
Re: Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. J Natl Cancer Inst (2009) 1.08
Mitoxantrone in epithelial carcinoma of the ovary. A Southwest Oncology Group study. Am J Clin Oncol (1984) 1.08
Identification of differentially expressed genes in organ-confined prostate cancer by gene expression array. Prostate (2001) 1.08
Predictors for cutaneous basal- and squamous-cell carcinoma among actinically damaged adults. Int J Cancer (2001) 1.07
A randomized, double blind, Phase III trial using oral beta-carotene supplementation for women with high-grade cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev (2001) 1.06
Tabular summary of pharmacokinetic parameters relevant to in vitro drug assay. Prog Clin Biol Res (1980) 1.06
Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother Pharmacol (1999) 1.05
Physical activity, body mass index, and prostaglandin E2 levels in rectal mucosa. J Natl Cancer Inst (1999) 1.05
Deficiency of Src homology 2-containing phosphatase 1 results in abnormalities in murine neutrophil function: studies in motheaten mice. J Immunol (2000) 1.05
Use of a food frequency questionnaire to screen for dietary eligibility in a randomized cancer prevention phase III trial. Cancer Epidemiol Biomarkers Prev (1997) 1.05
Investigating sun-damaged skin and actinic keratosis with optical coherence tomography: a pilot study. Technol Cancer Res Treat (2003) 1.04
Evidence for physical and functional association between EMB-5 and LIN-12 in Caenorhabditis elegans. Science (1996) 1.04
Subclavian MR arteriography: reduction of susceptibility artifact with short echo time and dilute gadopentetate dimeglumine. Radiology (2000) 1.04
Quality of nucleic acids extracted from fresh prostatic tissue obtained from TURP procedures. J Urol (2000) 1.03
Quantitation of the number of cells within tumor colonies in semisolid medium and their growth as oblate spheroids. Cancer Res (1984) 1.03
Antiproliferative effect of nonsteroidal antiinflammatory drugs against human colon cancer cells. Cancer Epidemiol Biomarkers Prev (1994) 1.03
Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev (1997) 1.02